Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 1, 2016. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of June 30, 2016:
- Total issued Ordinary Shares: 5,363,861,303 (25p each).
- Treasury Shares held: 491,505,950.
- Total voting rights: 4,872,355,353.
No comparative data for prior periods is included in this specific text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,872,355,353) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (491,505,950) to calculate the correct denominator for ownership percentage calculations.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.